Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Major Japanese Finance Firms Fund iPS Patent Company

This article was originally published in PharmAsia News

Executive Summary

To speed up the transfer of induced pluripotent stem cell technology to the pharmaceutical industry for new drug development, Kyoto University announced May 16 that the university in conjunction with Daiwa Securities Group, Mitsui Sumitomo Bank and NIFSMC Venture Capitals will establish a patent management company in June. The company will handle iPS-related patent issues such as: paying royalty to patent holders and licensing patents to regenerative medicine and pharmaceutical companies. The three firms agreed to invest ¥210 million and will increase their investment to ¥1.2 billion. Kyodo University will invest through an intermediary corporation set up by its executives and researchers. The director of research at the university, Hiroshi Matsumoto, commented that the company will prevent certain groups or companies from buying a controlling stake in the iPS patent. (Click here for more - Japanese language

You may also be interested in...



BMS, Eisai Team Up To Accelerate Development Of Solid-Tumor ADC

The US firm gets development and co-commercial rights to MORAb-202 for $650m up front. BMS joins AstraZeneca, Merck & Co. and Gilead in recent ADC deal-making.

BIO 2021 Notebook: Best Practices For Business Development

The recently concluded BIO annual meeting included several sessions focused on the practice of business development. In this extra edition of our BIO 2021 notebook, Scrip collected observations about best practices for partnerships.

Blueprint Prepares To Take On Novartis In Advanced Systemic Mastocytosis

The company’s rollout plans for Ayvakit appear similar to its approach when it marketed the drug for GIST, with an education plan to help boost sales.

UsernamePublicRestriction

Register

SC068518

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel